Hillsdale Investment Management Inc. Boosts Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Hillsdale Investment Management Inc. grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,830 shares of the biotechnology company’s stock after acquiring an additional 310 shares during the quarter. Hillsdale Investment Management Inc. owned 0.08% of Blueprint Medicines worth $4,433,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BPMC. Quarry LP purchased a new position in shares of Blueprint Medicines during the third quarter worth approximately $32,000. R Squared Ltd purchased a new position in shares of Blueprint Medicines during the fourth quarter worth approximately $51,000. Asset Management One Co. Ltd. purchased a new position in shares of Blueprint Medicines during the fourth quarter worth approximately $88,000. Van ECK Associates Corp raised its stake in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines in the third quarter worth $108,000.

Blueprint Medicines Stock Up 0.3 %

NASDAQ:BPMC opened at $88.72 on Friday. The firm’s 50-day moving average price is $99.47 and its 200-day moving average price is $93.88. The company has a market capitalization of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a 1-year low of $80.68 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BPMC has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th. Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a “buy” rating and a $135.00 target price on the stock. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Wolfe Research initiated coverage on shares of Blueprint Medicines in a research note on Tuesday. They issued an “outperform” rating on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $124.95.

Insider Activity at Blueprint Medicines

In related news, insider Ariel Hurley sold 3,203 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,334 shares of company stock valued at $3,103,512. 4.21% of the stock is owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.